Lrig1 anticorps (C-Term)
Aperçu rapide pour Lrig1 anticorps (C-Term) (ABIN1881506)
Antigène
Voir toutes Lrig1 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Épitope
- AA 801-829, C-Term
-
Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogène
- This LRIG1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 801-829 amino acids from the C-terminal region of human LRIG1.
-
Isotype
- Ig Fraction
-
-
-
-
Indications d'application
- WB: 1:1000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- 4 °C,-20 °C
-
Date de péremption
- 6 months
-
-
-
: "Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity." dans: Journal of neuro-oncology, Vol. 94, Issue 2, pp. 183-94, (2009) (PubMed).
-
-
- Lrig1 (Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1))
-
Autre désignation
- LRIG1
-
Sujet
- LRIG1 act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.
-
Poids moléculaire
- 119113
-
NCBI Accession
- NP_056356
-
UniProt
- Q96JA1
Antigène
-